Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease

dc.creatorBarreto G.E.
dc.creatorIarkov A.
dc.creatorMoran V.E.
dc.date.accessioned2020-09-02T22:13:00Z
dc.date.accessioned2022-11-08T20:23:47Z
dc.date.available2020-09-02T22:13:00Z
dc.date.available2022-11-08T20:23:47Z
dc.date.created2020-09-02T22:13:00Z
dc.date.issued2015
dc.identifier7, JAN, -
dc.identifier16634365
dc.identifierhttps://hdl.handle.net/20.500.12728/3692
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5144992
dc.languageen
dc.publisherFrontiers Media S.A.
dc.subjectAkt(PKB)
dc.subjectBeta-amyloid
dc.subjectCotinine
dc.subjectNicotine
dc.subjectParkinson disease
dc.subjectSynucleinopathies
dc.subject3 (2,4 dimethoxybenzylidene)anabaseine
dc.subjectcotinine
dc.subjectdrug metabolite
dc.subjectnicotine
dc.subjectdopaminergic nerve cell
dc.subjectdrug effect
dc.subjectdrug safety
dc.subjecthuman
dc.subjectmemory
dc.subjectmotor performance
dc.subjectnerve cell plasticity
dc.subjectnervous system inflammation
dc.subjectnonhuman
dc.subjectoxidative stress
dc.subjectParkinson disease
dc.subjectprotein aggregation
dc.subjectReview
dc.titleBeneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease
dc.typeReview


Este ítem pertenece a la siguiente institución